- January 12, 2021
- Posted by: Bastion team
- Category: Markets
(RTTNews) – Vir Biotechnology, Inc. (VIR) and GlaxoSmithKline plc (GSK, GSK.L) announced Tuesday an agreement with the U.K.-based AGILE initiative to evaluate VIR-7832 in patients with mild to moderate COVID-19 in a Phase 1b/2a clinical trial.
The trial is due to begin in the first quarter of 2021.
VIR-7832 is a neutralizing COVID-19 antibody…
Recommended articles
- I tried out a new $1,500 at-home gym system that calls itself for 'Peloton for boxing' – here's what it was like
The Liteboxer at-home system. LiteboxerThe Liteboxer is an at-home boxing system that calls itself the "Peloton of boxing." Freelance writer Emily Price tried out the Liteboxer to see if it's worth it...(read more)
- Science and Technology of Advanced Materials Research: Article on building memory devices from biocomposite electronic materials wins the STAM Altmetrics Award for 2020
TSUKUBA, Japan, Jan. 18, 2021 /PRNewswire/ -- Natural biomaterials show potential for the next generation of green electronics due to their biocompatibility and biodegradability. When combined with ot...(read more)
- Fragrance Creators Association Launches COVID-19 State Vaccine Tracker
WASHINGTON, Jan. 14, 2021 /PRNewswire/ -- Fragrance Creators Association launched today its COVID-19 State Vaccine Tracker, which provides its member companies across the fragrance value chain with up...(read more)
- Google's Alphabet has 22% upside and will be the top FANG stock in 2021, BofA says
Charles Platiau/ReutersGoogle's parent Alphabet is Bank of America's top FANG-stock pick for the year ahead. In a wide-ranging overview note published Thursday, a group of Bank of America analysts led...(read more)
